Halotestin and many of its metabolites contain two polar hydroxyl groups, leading to intermolecular hydrogen bonding that increases their boiling point and reduces volatility. In order to attain a gaseous sample for GC-MS, the products of hydrolysis are extracted, dissolved in methanol and derivatised to form volatile trimethylsilyl (TMS) esters by adding "N"-methyl-"N"-trimethylsilyl-trifluoroacetamide (MSTFA) and trimethylsilylimidazole (TMSImi). Fluoxymesterone was first described in 1956 and was introduced for medical use in the United States in 1957. Over time the use of fluoxymesterone has become increasingly controversial and limited. "Fluoxymesterone" is the generic name of the drug and its , , , , and , while "fluoxymestérone" is its . Brand names of fluoxymesterone include Android-F, Androxy, Halotestin, Ora-Testryl, and Ultandren among others. Fluoxymesterone is one of the few AAS that remains available for medical use in the United States. The others (as of November 2017) are testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, methyltestosterone, oxandrolone, and oxymetholone. Availability of fluoxymesterone aside from the United States remains scarce, but it is marketed in some other countries such as Mexico, Moldova, and Taiwan. Fluoxymesterone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act.